JP2023508726A5 - - Google Patents

Info

Publication number
JP2023508726A5
JP2023508726A5 JP2022540579A JP2022540579A JP2023508726A5 JP 2023508726 A5 JP2023508726 A5 JP 2023508726A5 JP 2022540579 A JP2022540579 A JP 2022540579A JP 2022540579 A JP2022540579 A JP 2022540579A JP 2023508726 A5 JP2023508726 A5 JP 2023508726A5
Authority
JP
Japan
Prior art keywords
temperature
sensitive
substance according
active substance
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022540579A
Other languages
English (en)
Japanese (ja)
Other versions
JP7787075B2 (ja
JP2023508726A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/067506 external-priority patent/WO2021138447A1/en
Publication of JP2023508726A publication Critical patent/JP2023508726A/ja
Publication of JP2023508726A5 publication Critical patent/JP2023508726A5/ja
Priority to JP2025230795A priority Critical patent/JP2026031695A/ja
Application granted granted Critical
Publication of JP7787075B2 publication Critical patent/JP7787075B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022540579A 2019-12-31 2020-12-30 細胞及び組織への核酸及びタンパク質の温度ベースの一過性送達 Active JP7787075B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025230795A JP2026031695A (ja) 2019-12-31 2025-12-04 細胞及び組織への核酸及びタンパク質の温度ベースの一過性送達

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962955801P 2019-12-31 2019-12-31
US62/955,801 2019-12-31
US202062992700P 2020-03-20 2020-03-20
US62/992,700 2020-03-20
PCT/US2020/067506 WO2021138447A1 (en) 2019-12-31 2020-12-30 Temperature-based transient delivery of nucleic acids and proteins to cells and tissues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025230795A Division JP2026031695A (ja) 2019-12-31 2025-12-04 細胞及び組織への核酸及びタンパク質の温度ベースの一過性送達

Publications (3)

Publication Number Publication Date
JP2023508726A JP2023508726A (ja) 2023-03-03
JP2023508726A5 true JP2023508726A5 (cg-RX-API-DMAC7.html) 2024-01-09
JP7787075B2 JP7787075B2 (ja) 2025-12-16

Family

ID=76687429

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022540579A Active JP7787075B2 (ja) 2019-12-31 2020-12-30 細胞及び組織への核酸及びタンパク質の温度ベースの一過性送達
JP2025230795A Pending JP2026031695A (ja) 2019-12-31 2025-12-04 細胞及び組織への核酸及びタンパク質の温度ベースの一過性送達

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025230795A Pending JP2026031695A (ja) 2019-12-31 2025-12-04 細胞及び組織への核酸及びタンパク質の温度ベースの一過性送達

Country Status (10)

Country Link
US (3) US11421248B2 (cg-RX-API-DMAC7.html)
EP (1) EP4085130A4 (cg-RX-API-DMAC7.html)
JP (2) JP7787075B2 (cg-RX-API-DMAC7.html)
KR (1) KR102764120B1 (cg-RX-API-DMAC7.html)
CN (2) CN116134131A (cg-RX-API-DMAC7.html)
AU (1) AU2020417800A1 (cg-RX-API-DMAC7.html)
CA (1) CA3162690A1 (cg-RX-API-DMAC7.html)
IL (1) IL294290A (cg-RX-API-DMAC7.html)
MX (1) MX2022007905A (cg-RX-API-DMAC7.html)
WO (1) WO2021138447A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
KR102764120B1 (ko) 2019-12-31 2025-02-06 엘릭서젠 쎄라퓨틱스, 인크. 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
TWI891771B (zh) 2020-04-17 2025-08-01 美商Vlp醫療股份有限公司 冠狀病毒疫苗
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
MX2023014564A (es) * 2021-06-17 2024-03-05 Elixirgen Therapeutics Inc Vacunas de arn autorreplicante, controlables por temperatura, para enfermedades virales.
JP2024533123A (ja) * 2021-09-02 2024-09-12 エリクサージェン セラピューティクス,インコーポレイティド がんのための温度制御可能なrna免疫療法
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
EP4473544A1 (en) * 2022-02-04 2024-12-11 Elixirgen Therapeutics, Inc. Cell therapy protocol systems and methods
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024112821A1 (en) 2022-11-22 2024-05-30 Elixirgen Therapeutics, Inc. Antigens for cancer immunotherapy

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
EP0819250B1 (en) 1995-04-06 2006-09-20 Miltenyi Biotec Inc. Multiparameter cell separation using releasable colloidal magnetic particles
US6458560B1 (en) 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
AU757549B2 (en) 1998-03-27 2003-02-27 Cytos Biotechnology Ag Inducible alphaviral gene expression system
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
CA2373300C (en) 1999-04-14 2012-02-21 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2000070070A1 (en) 1999-05-18 2000-11-23 Dnavec Research Inc. Paramyxoviridae virus vector defective in envelope gene
US20030232324A1 (en) 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
CA2448066A1 (en) 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
BR0313113A (pt) 2002-08-13 2005-06-28 Akzo Nobel Nv Replicon de um pestivìrus partìcula viral infecciosa de pestivìrus, método para a produção da mesma, e, vacina
US7820181B2 (en) * 2002-09-18 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
WO2004055161A2 (en) 2002-12-12 2004-07-01 The Board Of Regents Of The University Of Texas System Large scale production of packaged alphavirus replicons
AU2003297041B2 (en) 2002-12-13 2009-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
US20050282279A1 (en) * 2003-05-29 2005-12-22 Hwu Paul L Expression vector encoding coronavirus-like particle
WO2004108937A1 (en) * 2003-06-04 2004-12-16 Bioleaders Corporation Cell surface expression vector of sars virus antigen and microorganisms transformed thereby
US7541038B2 (en) 2003-06-05 2009-06-02 Wyeth Holdings Corporation Fusogenic, self-propagating blebs as immunogenic compositions
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
US7332322B2 (en) 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
US7998733B2 (en) 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
JP4478788B2 (ja) 2005-05-27 2010-06-09 独立行政法人産業技術総合研究所 センダイウイルス温度感受性株由来のウイルスベクター
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
WO2007098267A2 (en) 2006-02-27 2007-08-30 The Board Of Regents Of The University Of Texas System Pseudoinfectious flavivirus and uses thereof
US20090047255A1 (en) 2006-11-03 2009-02-19 Alphavax, Inc. Alphavirus and Alphavirus Replicon Particle Formulations and Methods
MX352947B (es) 2007-02-27 2017-12-14 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
US8748591B2 (en) 2007-04-17 2014-06-10 The Board Of Regents Of The University Of Texas System Chimeric sindbis-western equine encephalitis virus and uses thereof
EP2143794A1 (en) * 2007-04-27 2010-01-13 Kyushu University, National University Corporation Viral vector for gene therapy
WO2009079185A2 (en) * 2007-11-26 2009-06-25 Novartis Vaccines And Diagnostics, Inc. Methods of generating alphavirus particles
WO2009072610A1 (ja) 2007-12-05 2009-06-11 International Institute Of Cancer Immunology, Inc. 癌ワクチン組成物
JP5758632B2 (ja) 2008-01-24 2015-08-05 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用
EP2130912A1 (en) 2008-06-04 2009-12-09 Institut für Viruskrankeiten und Immunprophylaxe Pestivirus replicons providing an RNA-based viral vector system
WO2010008054A1 (ja) 2008-07-16 2010-01-21 ディナベック株式会社 染色体非組み込み型ウイルスベクターを用いてリプログラムされた細胞を製造する方法
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
US9402890B2 (en) 2011-02-01 2016-08-02 Uab Research Foundation Methods and compositions for pseudoinfectious alphaviruses
US9636410B2 (en) * 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
EP3520810A3 (en) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
AU2013266496B2 (en) 2012-05-21 2018-08-09 The Regents Of The University Of California Generation of human iPS cells by a synthetic self- replicative RNA
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
WO2014089513A1 (en) 2012-12-06 2014-06-12 Synthetic Genomics, Inc. Autonomous replication sequences and episomal dna molecules
LT2945647T (lt) 2013-01-15 2021-02-25 Memorial Sloan Kettering Cancer Center Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
WO2014134539A1 (en) 2013-02-28 2014-09-04 President And Fellows Of Harvard College Methods and compositions for mobilizing stem cells
EP2968392B1 (en) 2013-03-15 2020-08-05 Elixirgen Therapeutics, Inc. Methods of using zscan4 for rejuvenating human cells
US12374421B2 (en) 2013-06-10 2025-07-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2015046229A1 (ja) 2013-09-24 2015-04-02 ディナベック株式会社 多能性幹細胞の誘導効率を改善する方法
AU2014369774B2 (en) * 2013-12-20 2020-11-26 Boehringer Ingelheim Vetmedica Gmbh PRRS virus variant, European PRRS virus cDNA clone, and uses thereof
US10174317B2 (en) 2014-02-13 2019-01-08 Synthetic Genomics, Inc. Recombinant RNA particles and methods of use
US10266834B2 (en) 2014-02-13 2019-04-23 Synthetic Genomics, Inc. Recombinant RNA particles and methods of producing proteins
JP6769880B2 (ja) 2015-02-02 2020-10-14 株式会社Idファーマ 改良されたマイナス鎖rnaウイルスベクター
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
JP6913032B2 (ja) * 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
US10695385B2 (en) 2015-06-25 2020-06-30 National University Corporation Kobe University Oral cancer vaccine
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
WO2017026776A1 (en) 2015-08-10 2017-02-16 Cellivery Therapeutics, Inc. Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof
US10166281B2 (en) 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
DK3375874T3 (da) 2015-11-13 2022-05-09 Id Pharma Co Ltd Forbedret paramyxovirus-vektor
SG11201804197RA (en) 2015-11-18 2018-06-28 Orbis Health Solutions Llc T7 alpha viral vector system
HUE059694T2 (hu) 2015-11-20 2022-12-28 Memorial Sloan Kettering Cancer Center Készítmény rák kezelésére
GB201603374D0 (en) 2016-02-26 2016-04-13 Ucl Business Plc Packaging cell
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ,インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
WO2017208191A1 (en) 2016-06-02 2017-12-07 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
US20190216956A1 (en) * 2016-07-27 2019-07-18 The Trustees Of Columbia University In The City Of New York Compositions for radiotherapy and uses thereof
ES2993107T3 (en) 2016-10-17 2024-12-23 Janssen Pharmaceuticals Inc Recombinant virus replicon systems and uses thereof
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
WO2018081318A1 (en) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
JP7788787B2 (ja) 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ,インコーポレーテッド 遺伝子発現増強のための組成物および方法
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
WO2018161092A1 (en) 2017-03-03 2018-09-07 New York University Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
WO2018170347A1 (en) * 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
US11015204B2 (en) 2017-05-31 2021-05-25 Arcturus Therapeutics, Inc. Synthesis and structure of high potency RNA therapeutics
KR102823029B1 (ko) 2017-12-20 2025-06-20 브이엘피 테라퓨틱스 인코포레이티드 알파바이러스 레플리콘 입자
KR20200111729A (ko) 2018-01-19 2020-09-29 얀센 파마슈티칼즈, 인코포레이티드 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
CN118436618A (zh) 2018-05-30 2024-08-06 川斯勒佰尔公司 信使rna疫苗及其用途
WO2021119545A1 (en) 2019-12-11 2021-06-17 Gritstone Bio, Inc. Durable vaccination
KR102764120B1 (ko) 2019-12-31 2025-02-06 엘릭서젠 쎄라퓨틱스, 인크. 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
MX2022007910A (es) 2019-12-31 2022-08-25 Elixirgen Therapeutics Inc Distribucion transitoria basada en temperatura de ácidos nucleicos y proteínas de zscan4 a células y tejidos.
US20230310581A1 (en) 2020-04-27 2023-10-05 Ohio State Innovation Foundation A live attenuated measles virus vectored vaccine for sars-cov-2
EP4168042A1 (en) 2020-06-19 2023-04-26 Ziphius Vaccines Self-amplifying sars-cov-2 rna vaccine

Similar Documents

Publication Publication Date Title
Millet et al. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis
Gorchakov et al. PKR-dependent and-independent mechanisms are involved in translational shutoff during Sindbis virus infection
Bivalkar-Mehla et al. Viral RNA silencing suppressors (RSS): novel strategy of viruses to ablate the host RNA interference (RNAi) defense system
Siu et al. Antiviral RNA interference responses induced by Semliki Forest virus infection of mosquito cells: characterization, origin, and frequency-dependent functions of virus-derived small interfering RNAs
McInerney et al. Importance of eIF2α phosphorylation and stress granule assembly in alphavirus translation regulation
Rayner et al. Alphavirus vectors and vaccination
Liljeström Alphavirus expression systems
JP2015527296A5 (cg-RX-API-DMAC7.html)
Li et al. Diverse roles of host RNA binding proteins in RNA virus replication
Barr et al. Role of the intergenic dinucleotide in vesicular stomatitis virus RNA transcription
Qian et al. The capsid protein of Semliki Forest virus antagonizes RNA interference in mammalian cells
NZ603790A (en) Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
JP2020500536A5 (cg-RX-API-DMAC7.html)
Rezelj et al. Generation of mutant Uukuniemi viruses lacking the nonstructural protein NSs by reverse genetics indicates that NSs is a weak interferon antagonist
Morazzani et al. Proteolytic cleavage of host proteins by the Group IV viral proteases of Venezuelan equine encephalitis virus and Zika virus
Brennan et al. Mapping of transcription termination within the S segment of SFTS phlebovirus facilitated generation of NSs deletant viruses
JP2019527055A5 (cg-RX-API-DMAC7.html)
Heaton Harnessing host–virus evolution in antiviral therapy and immunotherapy
JP2019509750A5 (cg-RX-API-DMAC7.html)
Liu et al. An optimized circular polymerase extension reaction-based method for functional analysis of SARS-CoV-2
Rouxel et al. Attenuated infectious hematopoietic necrosis virus with rearranged gene order as potential vaccine
AR114942A1 (es) Partícula de replicón de alfavirus
Atasheva et al. Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation
Schlesinger RNA viruses as vectors for the expression of heterologous proteins
Mayuri et al. Role for conserved residues of Sindbis virus nonstructural protein 2 methyltransferase-like domain in regulation of minus-strand synthesis and development of cytopathic infection